Raju Mohan, Ventyx Biosciences CEO

Ven­tyx sprints to Wall Street less than a year af­ter emerg­ing from stealth

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

It took sev­en months from ex­it­ing “qui­et mode” for Ven­tyx Bio­sciences to land its very own stock tick­er, rais­ing $165 mil­lion in ven­ture funds along the way.

Now, af­ter pric­ing a mas­sive $151.5 mil­lion IPO, the Encini­tas, CA-based biotech is gun­ning for Phase II.

Ven­tyx priced close to 9.5 mil­lion shares at $16 apiece on Wednes­day, the mid­point of its $15 to $17 range. CEO Ra­ju Mo­han filed the S-1 pa­pers at the end of Sep­tem­ber, just over a week af­ter un­veil­ing a $114 mil­lion Se­ries B round. He pen­ciled in the stan­dard fig­ure of $100 mil­lion at first, like­ly know­ing that in the last year, it’s been com­mon for biotechs to raise much more than those ini­tial es­ti­mates.

Mo­han al­so tapped a fa­mil­iar face to chair the com­pa­ny’s board of di­rec­tors last month: Sheila Gu­jrathi, who has been qui­et­ly sup­port­ing Ven­tyx all along. The for­mer Gos­samer Bio CEO made a small in­vest­ment in Ven­tyx’s Se­ries A, which took place be­tween Feb­ru­ary and June 2021, ac­cord­ing to SEC pa­pers.

Sheila Gu­jrathi

Now the com­pa­ny will look to chal­lenge Zeposia, one of the top drugs Gu­jrathi de­vel­oped while at Re­cep­tos. Ven­tyx is hop­ing its S1P1R mod­u­la­tor VTX002 will prove to be a bet­ter op­tion in ul­cer­a­tive col­i­tis, par­tic­u­lar­ly avoid­ing some of Zeposia’s warn­ings around liv­er in­jury and mac­u­lar ede­ma screen­ing. That can­di­date’s head­ed for Phase II by the end of the year, ac­cord­ing to the S-1, and Ven­tyx will use be­tween $45 mil­lion and $55 mil­lion of the IPO funds to get it done.

Al­so head­ed for Phase II is Ven­tyx’s oral TYK2 in­hibitor VTX958 — the com­pa­ny’s lead pro­gram, de­spite the fact that it ap­pears to be slight­ly be­hind VTX002 on the de­vel­op­ment time­line. It’s de­signed to tar­get au­toim­mune dis­eases, with pso­ri­a­sis be­ing the first tar­get. Rough­ly $75 mil­lion to $85 mil­lion of the IPO funds are tagged to bring the can­di­date through Phase II in that in­di­ca­tion.

The re­designed pipeline com­bines pro­grams from three com­pa­nies all found­ed by Mo­han and New Sci­ence Ven­tures. VTX958 was plucked straight from the orig­i­nal Ven­tyx formed in 2019.

A third can­di­date tar­get­ing the NL­RP3 in­flam­ma­some will en­ter the clin­ic by the end of the year, the S-1 states. The NL­RP3 in­flam­ma­some is a key sig­nal­ing pro­tein com­plex in the in­nate im­mune sys­tem, and Ven­tyx thinks in­hibit­ing it could treat a range of sys­temic in­flam­ma­to­ry con­di­tions, such as car­dio­vas­cu­lar, he­pat­ic, re­nal and rheuma­to­log­ic dis­eases.

The idea re­ceived a big boost back in 2017, when No­var­tis pub­lished da­ta show­ing that in­hibit­ing IL-1ß, a cy­tokine re­leased by NL­RP3, re­duced the risk of heart dis­ease and stroke.

When all is said and done, Mo­han will hold just over 4% of shares, while New Sci­ence Ven­tures will have a 37.73% stake. ven­Bio Part­ners, which par­tic­i­pat­ed in the Se­ries B round, takes a 9.98% piece of the cake.

Ven­tyx will list un­der the tick­er $VTYX.

Pi­o­neer­ing Click Chem­istry in Hu­mans

Reimagining cancer treatments

Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, which is nearly one in six deaths. Recently, we have seen incredible advances in novel cancer therapies such as immune checkpoint inhibitors, cell therapies, and antibody-drug conjugates that have revamped cancer care and improved survival rates for patients.

Despite this significant progress in therapeutic targeting, why are we still seeing such a high mortality rate? The reason is that promising therapies are often limited by their therapeutic index, which is a measure of the effective dose of a drug, relative to its safety. If we could broaden the therapeutic indices of currently available medicines, it would revolutionize cancer treatments. We are still on the quest to find the ultimate cancer medicine – highly effective in several cancer types, safe, and precisely targeted to the tumor site.

Ivan Cheung, Eisai US chairman and CEO

Bio­gen, Ei­sai re­fresh amy­loid hy­poth­e­sis with PhI­II show­ing Alzheimer's med slows cog­ni­tive de­cline

In the first look at Phase III data for lecanemab, Eisai and Biogen’s follow-up Alzheimer’s drug to the embattled Aduhelm launch, results show the drug passed with flying colors on a test looking at memory, problem solving and other dementia metrics.

One of the most-watched Alzheimer’s therapies in the clinic, lecanemab met the study’s primary goal on the CDR-SB — Clinical Dementia Rating-Sum of Boxes — giving the biotech the confidence to ask for full approval in the US, EU and Japan by next March 31. The experimental drug reduced clinical decline on the scale by 27% compared to placebo at 18 months, the companies said Tuesday night Eastern time and Wednesday morning in Japan.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,200+ biopharma pros reading Endpoints daily — and it's free.

Nooman Haque, head of life sciences and healthcare at Silicon Valley Bank, and John Carroll

I’m head­ed to Lon­don soon for #EU­BIO22. Care to join me?

It was great getting back to a live ESMO conference/webinar in Paris followed by a live pop-up event for the Endpoints 11 in Boston. We’re staying on the road in October with our return for a live/streaming EUBIO22 in London.

Silicon Valley Bank’s Nooman Haque and I are once again jumping back into the thick of it with a slate of virtual and live events on October 12. I’ll get the ball rolling with a virtual fireside chat with Novo Nordisk R&D chief Marcus Schindler, covering their pipeline plans and BD work.

Gilead names 'k­ing­pin­s' in coun­ter­feit HIV med law­suit

Gilead is mounting its counterfeit drug lawsuit, naming two “kingpins” and a complex network of conspirators who allegedly sold imitation bottles of its HIV meds, some of which ended up in US pharmacies.

The pharma giant on Wednesday provided an update on what it called a “large-scale, sophisticated counterfeiting conspiracy,” accusing two new defendants of “leading and orchestrating” a scheme to sell hundreds of millions of dollars in illegitimate drugs posing as meds such as Biktarvy and Descovy.

Vlad Coric, Biohaven CEO (Photo Credit: Andrew Venditti)

As Amy­lyx de­ci­sion waits in the wings, Bio­haven’s ALS drug sinks (again) in plat­form tri­al

The FDA’s decision on Amylyx’s ALS drug is set to come out sometime Thursday. In a space with few drugs, any approval would be a major landmark.

But elsewhere in the ALS field, things are a bit more tepid.

Thursday morning, Biohaven announced that its drug verdiperstat failed its arm of an ALS platform trial led by Massachusetts General Hospital. According to a press release, the drug did not meet its primary endpoint — improvement on an ALS functional status test — or any key secondary endpoints at 24 weeks. The trial had enrolled 167 patients, giving them either verdiperstat or placebo twice a day.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,200+ biopharma pros reading Endpoints daily — and it's free.

Work taking place in the clean rooms at Vor (Credit: Vor)

Vor Bio opts to keep man­u­fac­tur­ing op­er­a­tions in-house for de­vel­op­ing stem cell, CAR-T ther­a­pies

While it is not uncommon for a biotech to go down the route of having the product manufactured by a contract organization, one small biotech is looking to keep its card close to its chest.

Vor Biopharma has started manufacturing operations at an in-house facility at its HQ in Cambridge, MA after beginning construction last summer.

According to the biotech, the facility aims to develop Vor’s hematopoietic stem cells (eHSCs) and CAR-T therapies for patients with blood cancers. The site will initially manufacture a clinical supply of its candidate VCAR33allo to support its IND, which is slated to be submitted in the first half of next year. It also plans to transfer the production of VOR33 to the facility. Vor is getting to work quickly as engineering runs for VCAR33allo has started this week.

Tar­sus looks to raise aware­ness of eye­lid mite dis­ease in cam­paign aimed at eye­care spe­cial­ists

Eyelid mite disease may be “gross” but it’s also fairly common, affecting about 25 million people in the US.

Called demodex blepharitis, it’s a well-known condition among eyecare professionals, but they often don’t always realize how common it is. Tarsus Pharmaceuticals wants to change that with a new awareness campaign called “Look at the Lids.”

The campaign and website debut Thursday — just three weeks after Tarsus filed for FDA approval for a drug that treats the disease.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,200+ biopharma pros reading Endpoints daily — and it's free.

Marcelo Bigal, Ventus Therapeutics CEO

No­vo Nordisk joins No­var­tis, Roche in NL­RP3 are­na, bet­ting $70M cash on NASH, car­diometa­bol­ic us­es

As a drug target, the NLRP3 inflammasome has drawn serious interest from Big Pharma, inspiring a series of M&A deals from Novartis and Roche on top of venture investments by others. Now Novo Nordisk is jumping on the bandwagon — and the Danish pharma giant is taking the target where it knows best.

Novo Nordisk is getting its NLRP3 inhibitors from Ventus Therapeutics, a Versant-backed startup that set out to make some of the best NLRP3 drugs out there by incorporating new insights into the structure of the target complex.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 151,200+ biopharma pros reading Endpoints daily — and it's free.

Aim­ing for fourth nod, Sarep­ta files an­oth­er DMD gene ther­a­py to FDA; Ax­some head­ed to­ward mi­graine re­sub­mis­sion

Sarepta Therapeutics has filed the data needed for an FDA accelerated approval, which would be the biotech’s fourth if granted by the agency.

The biotech has yet to complete confirmatory trials for those first three conditional nods. The filing for its fourth Duchenne muscular dystrophy treatment, disclosed Thursday, is not a surprise. Sarepta said in late-July it would do so after releasing positive results for the Roche-partnered gene therapy.